Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2007 Jul 9;204(7):1571–1582. doi: 10.1084/jem.20070058

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2007, The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 1. — GPCR and collagen agonists fail to trigger LAD-III–derived platelet aggregation caused by their inability to trigger high affinity α_IIbβ₃ integrin. (A) Platelet aggregation induced by GPCR agonists, collagen, and the vWF agonist ristocetin. Figures depict treatments at time 0 of either healthy control (black line) or LAD patient K (gray line) platelets with epinephrine (first panel), arachidonic acid (second panel), collagen (third panel), or ristocetin (fourth panel), as indicated in the Materials and methods. (B) FACS staining of resting (gray line) and agonist-stimulated (black line) platelets derived from a healthy (age-matched) donor and LAD patient K with the α_IIbβ₃ ligand mimetic mAb PAC-1. Vertical lines depict the mean intensity of background staining with an isotype-matched control mAb. Small graphs depict the total surface α_IIbβ₃ levels on these stimulated platelets. Similar results were obtained with LAD patient A.